Transcenta announces collaboration with agilent to develop a claudin18.2 companion diagnostic to support osemitamab (tst001) global phase iii trial

Princeton, n.j. and suzhou, china , april 8, 2024 /prnewswire/ -- transcenta holding limited ("transcenta") (hkex: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and agilent technologies, announce a collaboration to develop a claudin18.2 (cldn18.2) companion diagnostic to support transtar301 global phase iii pivotal trial of osemitamab (tst001) in combination with nivolumab and chemotherapy as first-line treatment in patients with cldn18.2 expressing locally advanced or metastatic gastric or gastroesophageal (g/gej) adenocarcinoma.
A Ratings Summary
A Quant Ranking